BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO (berotralstat)

RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO.

The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and Outcomes Research conference (ISPOR), which was held in Atlanta from May 5-8, 2024.

“The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization. This outcome provides a compelling argument that ORLADEYO, which is known to be effective in reducing HAE morbidity, is also a cost-effective strategy for patient management. By demonstrating the collective benefit of ORLADEYO therapy for patients and payers alike, this study represents an important step towards the goal of a normal life for patients with HAE,” said Sandra Christiansen, MD, professor of medicine and director of translational research at the US HAEA Angioedema Center at the University of California, San Diego.

Reductions in Real-World Healthcare Resource Utilization Among United States Hereditary Angioedema (HAE) Patients Following Berotralstat Initiation (Poster #EE477)

The poster detailed findings from a retrospective real-world study that featured analysis of administrative claims data of patients with HAE in the United States. The analysis focused on eligible patients who initiated ORLADEYO between December 2020 and December 2022 who had a baseline of a minimum of six months of continuous health plan enrollment prior to starting ORLADEYO, including commercial and public health plans.

In addition to the overall study population (n=260), results were stratified by two subgroups: patients who had a history of being treated with HAE long-term prophylaxis (LTP) (n=126) and patients who were naïve to LTP but had a history of receiving on-demand treatment (n=67). Average (median) follow-up duration was 12 (13) months for the overall study population, 13 (13) months for LTP treatment-experienced patients, and 13 (14) for LTP treatment-naïve patients with prior on-demand treatment.